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Abstract
The importance of growth factors has been recognized for over five decades; however their utilization in medicine has yet
to be fully realized. This is because free growth factors have short half-lives in plasma, making direct injection inefficient.
Many growth factors are anchored and protected by sulfated glycosaminoglycans in the body. We set out to explore the use
of heparin, a well-characterized sulfated glycosaminoglycan, for the controlled release of fibroblast growth factor-2 (FGF-2).
Heparin binds a multitude of growth factors and maintains their bioactivity for an extended period of time. We used a
biocompatible polycation to precipitate out the [heparin:FGF-2] complex from neutral buffer to form a release matrix. We
can control the release rate of FGF-2 from the resultant matrix by altering the molecular weight of the polycation. The FGF-2
released from the delivery complex maintained its bioactivity and initiated cellular responses that were at least as potent as
fresh bolus FGF-2 and fresh heparin stabilized FGF-2. This new delivery platform is not limited to FGF-2 but applicable to the
large family of heparin-binding growth factors.
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Introduction
Growth factors play an important role in regulating cell activity
and body function [1–3]. The short half-life of free growth factors
in plasma and potential side effects of systemic delivery indicate
that a controlled delivery strategy will be needed to achieve high
therapeutic efficacy [4–10]. Naturally occurring glycosaminogly-
cans, such as heparin, bind and stabilize many growth factors, and
at least in FGF-2, present it in a more bioactive form (Fig. 1 Left)
[11–14]. We reasoned that a biocompatible and biodegradable
polycation could bind heparin polyvalently and precipitate out the
[heparin:growth factor] complex by charge neutralization. The
use of intact heparin is inspired by the ternary structure of [FGF-
2:heparin:FGF-2 receptor] (Fig. 1). The arginine-based polyca-
tion, poly(argininate glyceryl succinate) (PAGS) is a minimalistic
mimetic of the cationic domain of the FGF-2 receptor. To the best
of our knowledge, this is the first report on controlled release of
growth factors using a self-assembled [polycation:heparin] matrix.
We discovered that the simple, self-assembled matrix formed by
PAGS, heparin, and FGF-2 in an aqueous buffer released
bioactive growth factor at a rate controlled by PAGS’s molecular
weight. Not only can this matrix control the FGF-2 release kinetics
but the released FGF-2 also possesses higher bioactivity than fresh
bolus FGF-2, and equals that of fresh heparin protected FGF-2.
Because heparin binds a broad spectrum of growth factors, this
delivery platform is expected to offer controlled release of many
growth factors with retention of bioactivity.
Growth factors are typically administered by bolus injections.
Although therapeutic effects may be observed in animal models
[15,16], many of the simple injection regimens reported no
significant improvement in phase II clinical trials [17,18]. This has
motivated a tremendous effort in controlled delivery of growth
factors, which typically uses one of the following approaches: 1.
Hydrogels [19–22], 2. polymer microparticles and films [23,24],
and 3. direct embedding of the growth factors in the delivery
matrix [25,26]. A large variety of biomaterials have been
employed as delivery vehicles including alginate-, chitosan-,
fibrin-, hyaluronan- and poly(ethylene glycol)-based hydrogels,
collagen, acrylic acid derivatives, poly(a-hydroxyl acid)s, and
inorganic salts such as calcium phosphate [27–30]. Heparin has
been used in growth factor delivery systems. For example, heparin-
coated alginate gels was used to deliver FGF-2 [31]. Heparin
crosslinked with poly(lactide-co-glycolide) (PLG) [32] and collagen
gel were used to deliver VEGF and FGF-2 [33]. Relatively few
studies have used intact heparin as an integral component of a
growth factor delivery vehicle, thus not taking full advantage of the
enhancement of heparin on growth factor potency. In the existing
studies using intact heparin, heparin-binding peptide epitopes
were used to yield the delivery vehicle. One used multi-arm
poly(ethylene glycol) modified with heparin-binding peptides (12 to
17mer) [34]. To the best of our knowledge, growth factor release
has yet to be reported using this approach. Another recent report
described the use of a heparin-binding peptide amphiphile to
deliver VEGF and FGF-2 [35]. The delivery vehicle required 15-
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e11017mer peptides and released 50% of the growth factors within 10
days in vitro. Both of these systems required expensive peptides and
it is not reported how the growth factor release will be controlled.
To the best of our knowledge, controlling growth factor release by
varying the polyvalency between a simple polycation and heparin
is unexplored.
Results
The self-assembly of the delivery matrix from PAGS and
heparin occurred in aqueous media with a white precipitate
formed immediately upon mixing of the two solutions (Fig. 2a).
The [PAGS:heparin] complex was a suspension and can be
pelleted by centrifugation. The charge of [PAGS:heparin]
complexes was examined via zeta potential titration by adding a
PAGS solution into a heparin solution (Fig. 2b). A solution of
heparin alone was approximately 230 mV. As PAGS solution was
added, the zeta potential increased following a sigmoidal curve. A
molar ratio of approximately 6/1 (mass ratio 35/1) of PAGS to
heparin resulted in an almost neutral complex. This ratio was used
for subsequent experiments because we expected it to afford the
highest FGF-2 loading. Scanning electron microscopy (SEM) was
used to further characterize the delivery matrix. SEM revealed
[PAGS:heparin] complexes as a matrix composed of fibers, sheets,
and beads (Fig. 2c). Fiber diameters were approximately 1 mmt o
sub-micron and the sheets ranged from 5–20 mm in dimension.
Examination of the matrix at 250006 magnification (Fig. 2d)
revealed the fibers were more like thin ribbons and the beads were
actually rings 0.5–1 mm in diameter.
The loading capacity and efficiency of [PAGS:heparin] to
conjugate FGF-2 were characterized using
125I-labeled FGF-2
(
125I-FGF-2, 1% of loaded growth factor). Loading efficiency was
investigated using two different molecular weights of PAGS. The
high molecular weight (HMW, Mn: 73,947, Mw: 238,802) PAGS
showed the highest loading efficiency of 66% (PAGS/heparin ratio
is 35) (Fig. 3a). It should be noted that FGF-2 incorporation was
calculated by measuring the amount of radioactivity present within
the sample and not by subtracting residual amount of FGF-2 in
supernatant, which would give loading efficiencies 10–20% higher
than reported. When the PAGS/heparin ratio was lowered to 21/
1 and 7/1 (ratios denote mass ratio unless otherwise noted), the
loading efficiency decreased to approximately 59%. Mass ratios
lower than 7/1 did not form visible precipitates. A higher mass
ratio of 49/1 was attempted but did not improve the loading
efficiency (data not shown). The low molecular weight (LMW, Mn:
63,944, Mw: 182,023) PAGS yielded a loading efficiency of 50% at
the 35/1 PAGS/heparin ratio. LMW PAGS of 21/1 and 7/1
ratios resulted in loading efficiencies of 43% and 40% respectively.
The higher molecular weight species of PAGS corresponded to
approximately 15% higher loading efficiency at all ratios
compared to the lower molecular weight species. The loading
capacity of [PAGS:heparin] complexes was examined using a 35/
1 ratio of LMW PAGS (Fig. 3b) and the total amount of FGF-2
added was 20, 200, and 2000 ng. In all cases, FGF-2 was loaded
with the same efficiency of 50%. This demonstrated that a
complex formed by 4 mg PAGS and 115 mg heparin can
incorporate at least 1 mg FGF-2, which would be sufficient for
most applications if the growth factor bioactivity is maintained.
The release of FGF-2 from the [PAGS:heparin:FGF-2]
complexes was monitored for 28 days using
125I-FGF-2. Two
different molecular weight species of PAGS were used to test the
hypothesis that increased polyvalency between PAGS and heparin
will reduce the affinity of FGF-2 to heparin and increase the
release kinetics. The release curves in PBS (Fig. 4a) indicated that
FGF-2 can be released for at least 28 days. The initial release of
approximately 7–10% was similar for both polymers. The release
profile of the HMW PAGS approached that of a power law and
52% of the loaded FGF-2 was released over 28 days. If the pattern
of the release continues, it should release FGF-2 for up to 110
days. The lower molecular weight species resulted in 19% of
loaded FGF-2 released over 28 days. The release also approached
that of a power law, and if the trend holds it should release FGF-2
Figure 1. Our delivery strategy was inspired by the interaction among growth factor, heparin and growth factor receptor. Left, the
crystal structure of the [FGF:Heparin:FGFR] complex kindly provided by Dr. Pellegrini. The proteins are shown as coils and heparin as a stick model.
The heparin-binding domains of FGFR and FGF are highlighted in pink and yellow respectively. Both analyses showed that the heparin-binding
regions contain a high density of positively charged amino acid residues such as arginine. Right, a possible model of the matrix formed by ionic
interactions between an arginine-based synthetic polycation and a [heparin:growth factor] complex.
doi:10.1371/journal.pone.0011017.g001
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necessary, but this experiment demonstrated the control, capabil-
ity, and flexibility of the delivery system. In order to mimic the in
vivo condition more closely, we conducted the release in the
presence of 0.1% bovine albumin (BSA) and 0.5% fetal bovine
serum (FBS) [24,31] using LMW PAGS. The addition of BSA had
a minor impact on the release of FGF-2 likely because BSA had a
low affinity to heparin (Kd of 4.3 mM) [36]. The presence of FBS
significantly increased the pellet size of the delivery matrix and
decreased the release rate of FGF-2. This is most likely caused by
the precipitation of serum protein in the presence of residual
cations in the [PAGS:heparin:FGF-2] complex, which acted as a
barrier to the release.
The bioactivity of released FGF-2 was investigated by two
different assays: endothelial cell proliferation and endothelial tube
formation. The ability of FGF-2 to stimulate proliferation of
endothelial cells has been well documented. HUVECs were
incubated with different groups of media for 48 hours and cell
number was measured via a Coulter counter (Fig. 5a). The tested
media included: [PAGS:heparin:FGF-2] release medium, negative
control without FGF-2, positive controls of fresh FGF-2 and fresh
[heparin:FGF-2]. HUVECs incubated with [PAGS:heparin:FGF-
2] day 1 release medium and fresh [FGF-2:heparin] medium
displayed approximately 1.7 fold increase (statistically significant)
over the negative control after 48 hours. Conversely, the cell
numbers in the bolus FGF-2 and the negative control showed no
statistical difference. Although increasing sample size may reveal
the difference, this implies the unstable nature of unprotected
FGF-2. Data using day 3 release media exhibited the same trend.
Thus, the FGF-2 released from [PAGS:heparin:FGF-2] complexes
was as potent as fresh, heparin-protected FGF-2.
Bioactivity of the released FGF-2 was further analyzed by
endothelial tube formation in growth-factor depleted MatrigelH.
Both HUVECs and HAECs were cultured with the same group of
media as the proliferation assay except that cells were cultured on
Matrigel (Fig. 5b). Image analysis on total endothelial tube length
was measured from a representative image of each well (n=4)
(Fig. 5c–f). HAECs incubated with [PAGS:heparin:FGF-2]
release media exhibited approximately a 4.5 fold increase in tube
length compared to the negative control. HUVECs displayed a 1.2
fold increase for the same pair. As observed with the proliferative
assay, FGF-2 released from [PAGS:heparin:FGF-2] complexes
Figure 2. The interaction between PAGS and heparin. [A] The binding of PAGS and heparin resulted in a white precipitate when combined in
an aqueous solution. [B] The titration of heparin using PAGS as monitored by zeta potential measurements. The complex was nearly neutral at a 35/1
mass ratio of PAGS/heparin. [C] SEM images revealed the [PAGS:heparin] complexes as a matrix composed of fibers and sheets, and beads (10006).
[D] Higher magnification (250006) revealed that many of the fiber are sub-micron in diameter and the beads were in fact rings.
doi:10.1371/journal.pone.0011017.g002
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(Fig. 5b), and there is no statistical significance between bolus
FGF-2 and the negative control. Further, HAECs cultured with
[PAGS:heparin:FGF-2] media was the only group that stimulated
statistically longer tube formation than bolus FGF-2 supplemented
media, outperforming fresh heparin-stabilized FGF-2, indictaing
the potential of the polycation-based delivery system. The high
bioactivity of released FGF-2 is likely attributable to using heparin
in its native form.
Discussion
The [PAGS:heparin] delivery vehicle takes advantage of
heparin’s ability to bind and protect numerous growth factors,
and mimics the anchoring of growth factors in the ECM. Heparin
is known to have a high affinity to FGF-2 (Kd: 8.6610
29M) [15],
which allows the self-assembly of the delivery matrix in aqueous
buffer for improved preservation of growth factor bioactivity.
Additionally, the delivery matrix is a fluidic suspension that can be
Figure 4. Release kinetics of FGF-2 in PBS and in the presence of serum proteins. [A] Release kinetics as examined by measuring the
amount of
125I-FGF-2 released from complexes. The percent of FGF-2 released from complexes was monitored over 28 days. Two different molecular
weight species of PAGS were used to characterize whether release kinetics were controllable. The LMW species of PAGS released nearly 20% of its
loaded growth factor, while the HMW species of PAGS released approximately 50% of incorporated growth factor over the same period of time. [B]
The addition of BSA had minor impact on the release FGF-2, which is consistent with the low affinity of BSA with heparin. On the other hand,
negatively charged serum proteins in FBS formed precipitate surrounding the delivery matrix, which decreased the FGF-2 release rate.
doi:10.1371/journal.pone.0011017.g004
Figure 3. Complex loading efficiency and capacity was investigated using
125I-FGF-2. [A] Loading efficiencies of different molecular
weight PAGS was investigated for different [PAGS:heparin] ratios. The higher molecular weight PAGS was more efficient at incorporating FGF-2 at all
[PAGS:heparin] ratios than the lower molecular weight polymer. A ratio of [35:1] was the most efficient at incorporating FGF-2 for both molecular
weight species. [B] The loading capacity of complexes was investigated for a [35:1] ratio of low molecular weight PAGS. This ratio demonstrated a
loading efficiency of 50% for all amounts of FGF-2. Statistical significance between [35:1] and other ratios was noted as ‘‘*’’, p,0.05.
doi:10.1371/journal.pone.0011017.g003
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delivery. The polyvalent interactions between PAGS and heparin
enables the control of FGF-2 release. A high molecular weight
PAGS would have a higher polyvalent affinity for heparin,
competing more efficiently against FGF-2 and leading to a faster
growth factor release. In contrast, a reduced polyvalency between
PAGS and heparin would result in a slower release of FGF-2. The
molecular weight also impacted the loading efficiency of FGF-2.
HMW PAGS is more efficient at conjugating [heparin:FGF-2]
than LMW PAGS. This suggests that the self-assembly of the
[PAGS:heparin:FGF-2] complex is a kinetically controlled process
and the larger polymers with more chain entanglement could
precipitate out the [heparin:FGF-2] complexes more quickly.
Refinement of the polymerization and purification process will
yield a wider range of PAGS molecular weights, thus expanding
the range of the release kinetics to potentially match a large range
of clinical applications. This delivery system is expected to be
applicable to the large family of heparin-binding growth factors,
which will be beneficial for many physiological processes that
require multiple growth factors.
Figure 5. The bioactivity of the FGF-2 released from the [PAGS:heparin] delviery matrix is higher than bolus FGF-2 and matches
that of heparin-protected FGF-2. Note that the growth factor in the release media were 1 and 3 days old, whereas the positive controls were
fresh. [A] The mitogenic potency of the released FGF-2 from days 1 and 3 examined using HUVECs indicated that the bioactivity of FGF-2 is well
maintained and matched that of the fresh heparin-protected FGF-2. [B] The released FGF-2 demonstrated ability to stimulate endothelial tube
formation as well as fresh heparin-protected FGF-2 and is the only group that was statistically significantly better than blous FGF-2 in HAECs.
Representative phase contrast micrographs of HUVECs incubated in: [C] no FGF-2, [D] fresh bolus FGF-2, [E] fresh [heparin:FGF-2], and [F]
[PAGS:heparin:FGF-2] release media. Statistical significance between the negative control and other experimental groups was noted as ‘‘*’’, p,0.05.
# denotes the statistical significance between an experimental group and the bolus FGF-2 group, p,0.05.
doi:10.1371/journal.pone.0011017.g005
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Materials
Succinic acid (TCI, Tokyo, Japan), arginine ethyl ester
dihydrochloride (Research Organics, Cleveland, OH), and other
reagents (Alfa Aesar, Medford, MA) were used without purification.
Meta-chloroperoxy benzoic acid (Acros Organics, Morris Plains,
NJ) was lyophilized overnight to remove water on a Labconco
FreeZone 2.5 (Kansas City, MO). Flash chromatography was
performed on a Buchi Fraction Collector C-660 equipped with a
UV photometer C-635 (Flawil, Switzerland). FGF-2 (R&DSystems,
Minneapolis, MN) is an N terminal truncated form of human FGF-
2 containing the amino acid residues Proline 10 to Serine 155. It is
carrier free and reconstituted in PBS with 1mM Dithiothreitol.
125I-
labeled FGF-2 was purchaced from Perkin Elmer (Waltham, MA).
Human umbilical vein endothelial cells (HUVECs) and human
aortic endothelial cells (HAECs) were gifts from Dr. Nerem and Dr.
Boyan laboratory respectively. Gel permeation chromatography
was performed on a GPCmax VE2001 with a 270 Dual Detector
(RALS and RI) using a Viscogel I-MBMMW column (Viscotek,
Houston, TX). The molecular weight and polydispersity of the
polymer are reported relative to polyethylene glycol standards.
Scanning electron microscopy (SEM) was performed with a Hitachi
S-800 SEM (15 kV, 3–5 nm spot size) or a Leo 1530 SEM (10 kV,
3 nm spot size). Radioactive measurements were measured on a
Cobra II Series Auto-Gamma Counter (Perkin Elmer, Waltham,
MA). Cell counting was performed on a Multisizer II Coulter Cell
Counter (Beckman Coulter, Fullerton, CA). Phase contrast images
were captured on a Nikon Eclipse TE2000-U (Melville, NY)
equipped witha4MPDiagnosticsSpotFlexdigitalcamera(Sterling
Heights, MI).
Synthesis of PAGS
The detailed synthesis and biocompatibility study will be
reported elsewhere. Briefly, PAGS was synthesized via polycon-
densation reaction of a 1:1 molar ratio of diglycidyl succinate and
arginine ethyl ester in anhydrous N,N-dimethylforamide under N2
at 60uC for 7 days. The resultant polymer was purified and
characterized by FTNMR, FTIR, differential scanning calorim-
etry, and gel permeation chromatography. High Molecular
Weight PAGS: Mn: 73,947, Mw: 238,802, PDI: 3.22, Low
Molecular Weight PAGS: 63,944, Mw: 182,023, PDI: 2.84.
Mw: 182,023, PDI: 2.84.
Preparation of [PAGS:heparin:FGF-2] complexes
PAGS (8 mg/ml) and heparin (10 mg/ml) were dissolved in D-
PBS with Ca
+2/Mg
+2. FGF-2 solution (100 mg/ml) was prepared
according to manufacturer’s protocol. Heparin and FGF-2 were
combined (114 mg/200 ng) and incubated at room temperature
(RT) for 15 min under mild agitation on an orbital shaker. PAGS
solution (0.5 ml) was added drop-wise to the mixture and allowed
to incubate at RT for 30 min with mild agitation. Samples were
centrifuged twice for 10 min at 12,1006g. Supernatant was
removed and fresh D-PBS was added to the pellet. Each sample
contained 4mg PAGS, 114mg heparin, and 200ng FGF-2 (molar
ratio: 428/80/1, mass ratio: 17500/500/1). Other ratios of
[PAGS:heparin:FGF-2] were also used and noted as such.
Characterization of [PAGS:heparin:FGF-2] complexes
[PAGS:heparin] complexes were prepared as described except
that molecular grade water was used. 750 ml of the solution was
diluted by half and analyzed using dynamic light scattering and
zeta potential measurements. To investigate morphology, [PAG-
S:heparin:FGF-2] complexes were prepared as described except
that molecular grade water was used. Otherwise, the large amount
of salt will overwhelm the SEM sample. 100 ml of the complex was
lyophilized on an SEM aluminum stub and sputtered with gold
before SEM examination.
FGF-2 loading efficiency
[PAGS:heparin:FGF-2] complexes were prepared in PBS with
1% of the FGF-2 being
125I-labeled FGF-2. After the complex was
pelleted via centrifugation, a 5% acetic acid solution in PBS with
Ca
+2/Mg
+2 was added. The pellet was then agitated overnight to
release all the FGF-2 and read on a gamma counter the following
day. The amount of FGF-2 loaded was calculated relative to a
control of
125I- FGF-2 subjected to identical treatments. Mass
ratios of [PAGS:heparin:FGF-2] examined included 17500/500/
1, 10500/500/1, 3500/500/1, 175000/5000/1, and 1750/50/1.
FGF-2 release kinetics
[PAGS:heparin:FGF-2] (mass ratio 17500/500/1) complex with
1%
125I-FGF-2 was prepared and pelleted. The supernatant was
replaced with 1 ml fresh PBS with Ca
+2/Mg
+2 and incubated at
37uC. The complex was centrifuged for 10 min at 12,1006ga n dt h e
supernatant wasanalyzed on a gamma counteron1,3,7, 10, 14, 17,
21, 24, and 28 days. 1 ml of fresh PBS was added to replenish the
supernatant at each time point. The release kinetics in the presence
of protein was performed following the same method except that 0.1
v/v% BSA or 0.5 v/v% FBS was added to the solution and the data
were collected on days 1, 3, 7, 10, 17, 21, 24, and 28.
Mitogenic potency of the released FGF-2
The [PAGS:heparin:FGF-2] (heparin/FGF-2 mass ratio, 25/1
[32]) pellets were incubated in 1 ml M-199 medium at 37uC. After
1 and 3 days, the suspension was centrifuged for 10 min at
12,1006g. The supernatant was removed and the tube replenished
with 1 ml fresh M-199 medium. HUVECs (P5-10) were seeded in
24-well tissue culture treated polystyrene (TCPS) plates at
approximately 10,000 cells/well with 1 ml M-199 growth media.
HUVECs were incubated overnight at 37uC, 5% CO2, washed
with PBS, and incubated with the supernatants from the
[PAGS:heparin:FGF-2] complexes, fresh FGF-2 of the same
concentration (11 ng/ml for day 1 and 7 ng/ml for day 3), fresh
heparin-stabilized FGF-2 of the same concentration, and basal
medium without FGF-2. The cells were then incubated for
another 48 hours before HUVECs were trypsinized and counted
on a Coulter counter. The bioactivity of FGF-2 released from
[PAGS:heparin] complexes was determined by comparing cell
proliferation with the controls.
Endothelial tube formation
[PAGS:heparin:FGF-2] complexes were pelleted and the
supernatant was replaced with 1 ml EGM-2 medium, and
incubated at 37uC. After 1 day, the suspension was centrifuged
for 10 min at 12,1006g. HAECs (P4-6) and HUVECS (P4-6) were
seeded on ECMatrix (Chemicon In Vitro Angiogenesis Assay Kit)
in a 96-well TCPS plate at 10,000 cells/well. 150 ml supernatant
was added to the HAECs culture and incubated for 8h.
Endothelial tube formation was quantified by measuring total
capillary tube length. Capillary tubes were measured from a
representative image of each well using Image Pro. These values
were averaged and tested for significance against HAECs
incubated with the basal medium, FGF-2- and [heparin:FGF-2]-
supplemented EGM-2 media under identical conditions. HUVEC
experiments were carried out in same manner except that M-199
media was used. Each experimental set contained 4 samples.
Control Growth Factor Release
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For each variable group tested there were at least three
replicates for the experimental and control samples. Multi-
comparisons ANOVA, Tukey Method, was used to statistically
compare the different experimental values; p,0.05 was considered
statistically significant. The results are reported as mean values 6
standard deviations.
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